新京报讯（记者王卡拉）近日，荣昌生物发布公告，其核心产品泰它西普的专利权期限获五年期限补偿，延长至2032年6月15日。泰它西普已被纳入国家医保目录，随着三个适应症相继获批上市，以及后续适应症的持续开发，专利保护期的延长，将为泰它西普赢得更多独占和开发市场的时间。 对于一款创新药而言，核心专利过期意味着市场竞争加剧、销售额下滑。而专利保护期的延长，将为该药再争取到更长的独占市场时间。因此，各大药...
Source Link新京报讯（记者王卡拉）近日，荣昌生物发布公告，其核心产品泰它西普的专利权期限获五年期限补偿，延长至2032年6月15日。泰它西普已被纳入国家医保目录，随着三个适应症相继获批上市，以及后续适应症的持续开发，专利保护期的延长，将为泰它西普赢得更多独占和开发市场的时间。 对于一款创新药而言，核心专利过期意味着市场竞争加剧、销售额下滑。而专利保护期的延长，将为该药再争取到更长的独占市场时间。因此，各大药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.